Expression of CD44v3 splice variant is associated with the visceral metastatic phenotype of human melanoma

被引：0
作者：
Döme B. [2 ]
Somlai B. [3 ]
Ladányi A. [4 ]
Fazekas K. [4 ]
Zöller M. [5 ]
Tímár J. [1 ]
机构：
[1] Department of Tumor Progression, National Institute of Oncology, 1122 Hungary
[2] First Institute of Pathology, Experimental Cancer Research, Semmelweis University of Medicine, Budapest
[3] Department of Dermato-Venerology, Semmelweis University, Budapest
[4] Department of Tumor Progression, National Institute of Oncology, Budapest
[5] Department of Tumor Progression and Immune Defense, German Cancer Research Center, Heidelberg
来源：
Virchows Archiv | 2001年 / 439卷 / 5期
关键词：
CD44v3; Immunohistochemistry; Malignant melanoma; Metastasis; MMP2; RT-PCR;
D O I：
10.1007/s004280100451
中图分类号：
学科分类号：
摘要：
We analyzed the immunohistochemical expression of the metastasis-associated protein, CD44v3, in 46 primary human malignant melanomas (MMs). This is the first time that the v3 splice variant of CD44 was found to be expressed in human melanomas (15 of 46), ranging from 3% to 35% of the cell population in the positive tumors. The expression of CD44v3 was observed in tumors thicker than 1.0 mm, and one-third of these tumors proved to be positive irrespective of the thickness. Patients were followed for a minimum of 61 months. The onset of lymph node or organ metastases occurred not later than 58 months and 60 months, respectively. Of the 15 CD44v3 positive tumors, 14 were observed in the organ metastatic tumor group, comprising the majority of those cases (14 of 21), and this association proved to be statistically significant compared with the non-metastatic (P<0.05) and lymph-node metastatic cases (P<0.01). CD44v3 expression in melanoma was also confirmed at the protein and messenger (mRNA) level in several human melanoma cell lines using flow cytometry and reverse transcriptase polymerase chain reaction analysis. In parallel to CD44v3, MMP-2 expression (determined using immunohistochemistry) was significantly elevated (P<0.05) but only in the organ metastatic group of MM. The 5-year survival of patients having thicker tumors than 1.0 mm (where v3 expression occurred) who had CD44v3+ tumors was significantly lower than those of the negative ones (35.7% versus 68.2%, respectively; P=0.025). Finally, we observed that the CD44v3-expressing tumors were characterized by significantly higher MMP-2 expression than the CD44v3-negative tumors (P<0.001), indicating a possible correlation between CD44v3- and MMP-2-positive phenotype and the organ metastatic potential of MM.
引用
收藏
页码：628 / 635
页数：7
相关论文
共 44 条
[1]  
Bennett K.L., Jackson D.G., Simon J.C., Tanczos E., Peach R., Modrell B., Stamenkovic I., Plowman G., Aruffo A., CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor, J Cell Biol, 128, pp. 687-698, (1995)
[2]  
Bishop N.J.A., Molecular pathology of melanoma, Cancer Metastasis Rev, 16, pp. 141-154, (1997)
[3]  
Busam K.J., Berwick M., Blessing K., Fandrey K., Kang S., Karaoli T., Fine J., Cochran A.J., White W.L., Rivers J., Et al., Tumor vascularity is not a prognostic factor for malignant melanoma of the skin, Am J Pathol, 147, pp. 1049-1056, (1995)
[4]  
Caligo M.A., Grammatico P., Cipollini G., Varesco L., Del Porto G., Bevilacqua G., A low NM23.H1 gene expression identifying high malignancy human melanomas, Melanoma Res, 4, pp. 179-184, (1994)
[5]  
De Wit P.E., Van Muijen G.N., De Waal R.M., Ruiter D.J., Pathology of malignant melanoma, including new markers and techniques in diagnosis and prognosis, Curr Opin Oncol, 8, pp. 143-151, (1996)
[6]  
Dietrich A., Tanczos E., Vanscheidt W., Schopf E., Simon J.C., The cell surface glycoprotein CD44 has been implicated in the progression and metastasis of certain human tumours including malignant melanoma (MM), Eur J Cancer, 33, pp. 926-930, (1997)
[7]  
Dome B., Somlai B., Timar J., The loss of NM23 protein in malignant melanoma predicts lymphatic spread without affecting survival, Anticancer Res, 20, pp. 3971-3974, (2000)
[8]  
Easty D.J., Maung K., Lascu I., Veron M., Fallowfield M.E., Hart I.R., Bennett D.C., Expression of NM23 in human mela-noma progression and metastasis, Br J Cancer, 74, pp. 109-114, (1996)
[9]  
Fernandez-Figueras M.T., Ariza A., Calatrava A., Puig L., Fernandez-Vasalo A., Ferrandiz C., CD44 and melano-cytic tumors: A possible role for standard CD44 in the epider-motropic spread of melanoma, J Cutan Pathol, 23, pp. 133-139, (1996)
[10]  
Florenes V.A., Aamdal S., Myklebost O., Maelandsmo G.M., Bruland O.S., Fodstad O., Levels of nm23 messenger RNA in metastatic malignant melanomas: Inverse correlation to disease progression, Cancer Res, 52, pp. 6088-6091, (1992)
12345